Ignite Creation Date:
2025-12-24 @ 7:11 PM
Ignite Modification Date:
2025-12-29 @ 3:39 AM
Study NCT ID:
NCT02226003
Status:
COMPLETED
Last Update Posted:
2018-09-13
First Post:
2014-08-25
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Efficacy and Safety of Ertugliflozin (MK-8835/PF-04971729) With Sitagliptin in the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Diet and Exercise (MK-8835-017)
Sponsor:
Merck Sharp & Dohme LLC
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2014-09-23
Start Date Type:
ACTUAL
Primary Completion Date:
2016-02-23
Primary Completion Date Type:
ACTUAL
Completion Date:
2016-02-23
Completion Date Type:
ACTUAL
First Submit Date:
2014-08-25
First Submit QC Date:
None
Study First Post Date:
2014-08-26
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2017-02-23
Results First Submit QC Date:
None
Results First Post Date:
2017-04-07
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2018-08-15
Last Update Post Date:
2018-09-13
Last Update Post Date Type:
ACTUAL